科兴制药与苑东生物共拓阿帕他胺片海外市场

Core Viewpoint - The strategic cooperation agreement between the company and Chengdu Yuandong Biopharmaceutical Co., Ltd. aims to enhance the commercialization of Apalutamide tablets in multiple international markets, focusing on prostate cancer treatment [1] Group 1 - The company has signed a strategic cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. in 2023 [1] - The agreement includes exclusive overseas commercialization authorization for Apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia, and Colombia [1] - This collaboration aims to deepen the partnership and promote the drug's entry into potential markets in Southeast Asia, the Middle East, and Latin America [1]